Novartis, Vertex and Ipsen announce new acquisitions as M&A activity surges in early July 2026

Biopharma’s merger and acquisition engine remains robust, with four companies revealing new deals within the first six days of July. The announcements add to a total of 45 acquisitions reported in the first half of the year.

Novartis, Vertex and Ipsen are among the firms extending the buying spree, each securing targets that together could be worth up to $12.6 billion. The deals reflect continued confidence in growth through strategic purchases.

Industry observers note that the pace of transactions suggests no sign of cooling off, as companies seek to expand pipelines and market reach ahead of the second half of 2026.